Breast Cancer Clinical Trials in Massachusetts

Showing 161-180 of 602 trials

MARGetuximab Or Trastuzumab (MARGOT)

NCT04425018

The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)

Breast CancerStage II Breast CancerStage III Breast Cancer+1 more

Dana-Farber Cancer Institute174 participantsStarted Jul 2020

Washington D.C., District of Columbia, United States • Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States +11 more locations

Active Not RecruitingPhase 26.3 miles

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

NCT03414684

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body. The interventions involved in this study are: * Carboplatin * Nivolumab

Breast Cancer

Dana-Farber Cancer Institute78 participantsStarted Jan 2018

Stamford, Connecticut, United States • Bangor, Maine, United States • Boston, Massachusetts, United States +7 more locations

MARGetuximab Or Trastuzumab (MARGOT)

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Breast Cancer Trials in Other Cities

Mirai-MRI: Validation of AI Models for Breast Cancer Risk

A Study of PF-06873600 in People With Cancer

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

The COMPASSION Study

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Study of AVZO-021 in Patients With Advanced Solid Tumors

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Other Conditions in Massachusetts